| Dr Hugh Samuel Brock, MD | |
|
501 Airport Rd, Rifle, CO 81650-8510 | |
| (706) 251-1100 | |
| Not Available |
| Full Name | Dr Hugh Samuel Brock |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 19 Years |
| Location | 501 Airport Rd, Rifle, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861543415 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207XS0114X | Orthopaedic Surgery - Adult Reconstructive Orthopaedic Surgery | MD2011-0409 (New Mexico) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Grand River Hospital District | Rifle, CO | Hospital |
| Valley View Hospital Association | Glenwood springs, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Grand River Hospital District | 7113837469 | 62 |
News Archive
A new online tool from the Center on Alcohol Marketing and Youth (CAMY) at the Johns Hopkins Bloomberg School of Public Health determines the extent of exposure to radio alcohol advertisements among young people ages 12 to 20 in 75 different media markets.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. The program is already in progress in Australia, where it was initiated in June 2009.
New research from scientists at the University of Maryland School of Medicine has found that tiny lumps of calcium phosphate may be an important triggering factor for age-related macular degeneration (AMD), a degenerative eye disease that can cause severe vision loss and blindness.
Pfizer Inc today announced new, longer-term data from the Intergroup Exemestane Study (IES) showing that women who switched to AROMASIN® (exemestane tablets) after taking tamoxifen for two to three years experienced a significant reduction (18%) in the risk of disease-free survival (DFS) events. In addition, IES showed that AROMASIN prolonged overall survival (OS) in the ER+/unknown population with a 14% reduction in the risk of dying. These results demonstrate that the benefits of treatment are maintained in long term follow-up. These results were presented at the joint ECCO 15/ESMO 34 meeting in Berlin, Germany.
› Verified 3 days ago
| Entity Name | Grand River Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124074042 PECOS PAC ID: 7113837469 Enrollment ID: O20040310000898 |
News Archive
A new online tool from the Center on Alcohol Marketing and Youth (CAMY) at the Johns Hopkins Bloomberg School of Public Health determines the extent of exposure to radio alcohol advertisements among young people ages 12 to 20 in 75 different media markets.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. The program is already in progress in Australia, where it was initiated in June 2009.
New research from scientists at the University of Maryland School of Medicine has found that tiny lumps of calcium phosphate may be an important triggering factor for age-related macular degeneration (AMD), a degenerative eye disease that can cause severe vision loss and blindness.
Pfizer Inc today announced new, longer-term data from the Intergroup Exemestane Study (IES) showing that women who switched to AROMASIN® (exemestane tablets) after taking tamoxifen for two to three years experienced a significant reduction (18%) in the risk of disease-free survival (DFS) events. In addition, IES showed that AROMASIN prolonged overall survival (OS) in the ER+/unknown population with a 14% reduction in the risk of dying. These results demonstrate that the benefits of treatment are maintained in long term follow-up. These results were presented at the joint ECCO 15/ESMO 34 meeting in Berlin, Germany.
› Verified 3 days ago
| Entity Name | Grand River Hospital District |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1649218991 PECOS PAC ID: 7113837469 Enrollment ID: O20170113000679 |
News Archive
A new online tool from the Center on Alcohol Marketing and Youth (CAMY) at the Johns Hopkins Bloomberg School of Public Health determines the extent of exposure to radio alcohol advertisements among young people ages 12 to 20 in 75 different media markets.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. The program is already in progress in Australia, where it was initiated in June 2009.
New research from scientists at the University of Maryland School of Medicine has found that tiny lumps of calcium phosphate may be an important triggering factor for age-related macular degeneration (AMD), a degenerative eye disease that can cause severe vision loss and blindness.
Pfizer Inc today announced new, longer-term data from the Intergroup Exemestane Study (IES) showing that women who switched to AROMASIN® (exemestane tablets) after taking tamoxifen for two to three years experienced a significant reduction (18%) in the risk of disease-free survival (DFS) events. In addition, IES showed that AROMASIN prolonged overall survival (OS) in the ER+/unknown population with a 14% reduction in the risk of dying. These results demonstrate that the benefits of treatment are maintained in long term follow-up. These results were presented at the joint ECCO 15/ESMO 34 meeting in Berlin, Germany.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Hugh Samuel Brock, MD 501 Airport Rd, Rifle, CO 81650-8510 Ph: (970) 625-1100 | Dr Hugh Samuel Brock, MD 501 Airport Rd, Rifle, CO 81650-8510 Ph: (706) 251-1100 |
News Archive
A new online tool from the Center on Alcohol Marketing and Youth (CAMY) at the Johns Hopkins Bloomberg School of Public Health determines the extent of exposure to radio alcohol advertisements among young people ages 12 to 20 in 75 different media markets.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. The program is already in progress in Australia, where it was initiated in June 2009.
New research from scientists at the University of Maryland School of Medicine has found that tiny lumps of calcium phosphate may be an important triggering factor for age-related macular degeneration (AMD), a degenerative eye disease that can cause severe vision loss and blindness.
Pfizer Inc today announced new, longer-term data from the Intergroup Exemestane Study (IES) showing that women who switched to AROMASIN® (exemestane tablets) after taking tamoxifen for two to three years experienced a significant reduction (18%) in the risk of disease-free survival (DFS) events. In addition, IES showed that AROMASIN prolonged overall survival (OS) in the ER+/unknown population with a 14% reduction in the risk of dying. These results demonstrate that the benefits of treatment are maintained in long term follow-up. These results were presented at the joint ECCO 15/ESMO 34 meeting in Berlin, Germany.
› Verified 3 days ago
Daniel Goldberg, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 501 Airport Rd Fl 6, Rifle, CO 81650 Phone: 970-625-1510 | |
Frank S Kopich, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 501 Airport Rd, Rifle, CO 81650 Phone: 970-625-1100 | |
Dr. Norman Lindsay Harris Jr., M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 501 Airport Rd, Rifle, CO 81650 Phone: 970-625-1100 | |
Robert Stephen Derkash, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 501 Airport Rd, Rifle, CO 81650 Phone: 970-625-1100 |